Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 6/20 | 1.00 |
| ▸ | BTK | Q06187 | 13/20 | 0.47 |
| ▸ | HCK | P08631 | 8/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 3/20 | 0.39 |
| ▸ | TEC | P42680 | 3/20 | 0.39 |
| ▸ | TXK | P42681 | 3/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20767487 | 1.00 | ITK (1.00) | ITKBTKHCKLCKAURKB | |
| SCHEMBL20767484 | 1.00 | ITK (1.00) | ITKBTKHCKLCKAURKB | |
| SCHEMBL807822 | 0.90 | ITK (0.81) | ITKBTKHCKLCKAURKB | |
| SCHEMBL25069003 | 0.87 | ITK (0.76) | ITKBTKHCKLCKAURKB | |
| SCHEMBL23409058 | 0.87 | ITK (0.76) | ITKBTKHCKLCKAURKB | |
| SCHEMBL25069002 | 0.86 | ITK (0.75) | ITKBTKHCKLCKAURKB | |
| SCHEMBL25069001 | 0.86 | ITK (0.75) | ITKBTKHCKLCKAURKB | |
| SCHEMBL22374670 | 0.83 | ITK (0.71) | ITKBTKHCKLCKAURKB | |
| SCHEMBL2398855 | 0.83 | ITK (0.70) | ITKBTKLCKAURKBTEC | |
| SCHEMBL2397738 | 0.83 | ITK (0.70) | ITKBTKLCKAURKBTEC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019040706-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VITILIGO | ACLARIS THERAPEUTICS, INC. (US) | 2019-02-28 | — | — | WO | disclosed |